company background image
ABEO

Abeona TherapeuticsNasdaqCM:ABEO Stock Report

Market Cap

US$91.0m

7D

0.2%

1Y

-31.9%

Updated

19 Oct, 2021

Data

Company Financials +
ABEO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ABEO Overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases.

Abeona Therapeutics Competitors

Baxter International

NYSE:BAX

US$39.8b

Grifols

BME:GRF

€11.5b

Harmonic Drive Systems

JASDAQ:6324

JP¥515.0b

Camurus

OM:CAMX

kr9.4b

Price History & Performance

Summary of all time highs, changes and price drops for Abeona Therapeutics
Historical stock prices
Current Share PriceUS$0.90
52 Week HighUS$0.84
52 Week LowUS$3.79
Beta1.52
1 Month Change-25.10%
3 Month Change-33.42%
1 Year Change-31.91%
3 Year Change-90.44%
5 Year Change-88.77%
Change since IPO-99.98%

Recent News & Updates

Aug 17
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Shareholder Returns

ABEOUS BiotechsUS Market
7D0.2%1.7%4.0%
1Y-31.9%15.6%30.5%

Return vs Industry: ABEO underperformed the US Biotechs industry which returned 13.6% over the past year.

Return vs Market: ABEO underperformed the US Market which returned 30% over the past year.

Price Volatility

Is ABEO's price volatile compared to industry and market?
ABEO volatility
ABEO Beta1.52
Industry Beta0.98
Market Beta1

Stable Share Price: ABEO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ABEO's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
197476Michael Amorosohttps://www.abeonatherapeutics.com

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs.

Abeona Therapeutics Fundamentals Summary

How do Abeona Therapeutics's earnings and revenue compare to its market cap?
ABEO fundamental statistics
Market CapUS$90.98m
Earnings (TTM)-US$54.27m
Revenue (TTM)US$10.00m

9.1x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ABEO income statement (TTM)
RevenueUS$10.00m
Cost of RevenueUS$31.86m
Gross Profit-US$21.86m
ExpensesUS$32.42m
Earnings-US$54.27m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.54
Gross Margin-218.58%
Net Profit Margin-542.74%
Debt/Equity Ratio2.1%

How did ABEO perform over the long term?

See historical performance and comparison

Valuation

Is Abeona Therapeutics undervalued compared to its fair value and its price relative to the market?

1.08x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ABEO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ABEO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ABEO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ABEO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ABEO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ABEO is good value based on its PB Ratio (1.1x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Abeona Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

40.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABEO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ABEO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ABEO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ABEO's revenue (80.5% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: ABEO's revenue (80.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ABEO's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Abeona Therapeutics performed over the past 5 years?

-28.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ABEO is currently unprofitable.

Growing Profit Margin: ABEO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ABEO is unprofitable, and losses have increased over the past 5 years at a rate of 28.2% per year.

Accelerating Growth: Unable to compare ABEO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABEO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: ABEO has a negative Return on Equity (-64.55%), as it is currently unprofitable.


Financial Health

How is Abeona Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ABEO's short term assets ($78.9M) exceed its short term liabilities ($41.9M).

Long Term Liabilities: ABEO's short term assets ($78.9M) exceed its long term liabilities ($4.7M).


Debt to Equity History and Analysis

Debt Level: ABEO's debt to equity ratio (2.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if ABEO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ABEO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ABEO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 27.3% each year


Dividend

What is Abeona Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABEO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABEO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABEO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABEO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABEO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.4yrs

Average management tenure


CEO

Michael Amoroso (43 yo)

0.92

Tenure

US$1,737,947

Compensation

Mr. Michael Amoroso serves as President and Director at Abeona Therapeutics Inc. since March 19, 2021 and Chief Executive Officer since November 01, 2020. Mr. Amoroso served as Chief Operating Officer of A...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD1.74M) is above average for companies of similar size in the US market ($USD545.22K).

Compensation vs Earnings: Insufficient data to compare Michael's compensation with company performance.


Leadership Team

Experienced Management: ABEO's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: ABEO's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ABEO insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.4%.


Top Shareholders

Company Information

Abeona Therapeutics Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Abeona Therapeutics Inc.
  • Ticker: ABEO
  • Exchange: NasdaqCM
  • Founded: 1974
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$90.983m
  • Shares outstanding: 101.23m
  • Website: https://www.abeonatherapeutics.com

Number of Employees


Location

  • Abeona Therapeutics Inc.
  • 1330 Avenue of the Americas
  • 33rd Floor
  • New York
  • New York
  • 10019
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/19 23:37
End of Day Share Price2021/10/19 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.